Market Analysis - Hypertension Congress 2020
As per a statement of World Health Organization (WHO), Hypertension is one of the silent killers in 21st century and is one of the biggest global public health concerns. Hypertension is major contributors of cardiac complications, stroke, heart diseases, kidney failure, blindness, including premature death and disabilities. Hypertension is curable as well as treatable for which there is a need of involvement from individual entities, government and private sectors, health workers, civil societies and moreover individual awareness is highly recommended.
As per the estimation of WHO, globally more than 1.13 billion of people are affected with Hypertension
among which less than 1 in each 5 is under control. Unhealthy diets, lack of physical activities, consumption of alcohol & tobacco are the main contributing factors of Hypertension
. To reduce the prevalence by 25% by 2025, WHO along with United States Center for Disease Control and Prevention launched Global heart Initiative in 2016.
or high Blood Pressure leads to 7.5million death cases which shares about 12.8% of all death cases recorded. Hypertension is also accounts about 57million disabilities adjusted life years which is about 3.7% of total adjusted life years. Hypertension is the primary risk factor of coronary heart disease, ischemic & haemorrhagic stroke.
Global prevalence of Hypertension
in adult aged>25 was about 40% in 2008. Between 1980 to 2008 the prevalence was moderate. But, due to sharp growth in population, ageing population the uncontrolled Hypertension
reached to 1 billion 2008 from 600 million. The prevalence of Hypertension
was highest in Africa (>40%) and lower in Americas (35%).
As per the research of some independent firm, global Hypertension
drug market is estimated to be $24.7billion in 2018 & expected to hit about $19.3 billion by 2029 with an annual CAGR of -2.3% in between 2019 to 2029. Main Drugs in the Hypertension
market are Tacleer, Uptravi, Opsumit, Letairis, Adcirca, Revatio, Adempas, Veletri, Oremitram, Tyvaso, Remodulin. Major classes of drugs used are: Calcium Channel Blockers, Diuretics, Beta Blockers Vasodilators, Angiotensin Converting Enzyme Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, and Renin Inhibitors. Major players in the anti-hypertensive drugs market are: Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Sanofi Aventis and United Therapeutics.
As per another survey, global Pulmonary Arterial Hypertension
(PAH) market is forecasted to touch $9.3billion by 2026 with an CAGR of 5.6% during 2019-2026. Rising cases of PAH and the support from federal Government and private organizations, development of Orphan Drug products for PAH is fuelling the growth of the market.
Conference Series is delighted to host the 4thInternational Conference on Hypertension & Cardiac Health (Hypertension Congress 2020) during March 25-26, 2020 at Tokyo, japan. Hypertension Congress 2020, is open to all the healthcare professional with an interest in Hypertension and Cardiovascular research & allied fields.
Hypertension 2020 Meeting is based on the theme “Exploring the new horizons to cure Hypertension & Cardiac diseases”.
This Hypertension Congress is not only provides a great platform to exchange ideas, discuss case studies, share research outputs in the area of Hypertension & Cardiac care, but also provide an opportunity to meet the experts across the globe and network. Hypertension 2020 will mark the presence of international and national leaders in the sector of Cardiovascular Research, leading clinicians working in Clinical trial projects, Physicians, Primary Healthcare Providers, Academic researchers, Business Delegates, Government officials and key decision makers.
The aim of this Hypertension meeting is to discuss the strategies for screening, prevention and treatment of High blood pressure and related cardiac events. This Hypertension Congress, Japan, includes several Plenary presentations, interactive sessions, Video presentations, Poster Presentations, Special case studies sessions, Young Research Forums, Networking sessions etc. The sessions in this Hypertension Conference will help the young investigators including healthcare practitioners, Primary healthcare providers, Academic investigators to acquire in depth knowledge from the basic study of Hypertension and Cardiac health to Clinical aspects of Hypertension and Cardiac Health management.